主页 / 领导层 / Dr. Patrick Smith
Dr. Patrick Smith Senior Vice President, Integrated Drug Development and Strategy

凭借 20 多年的全球药物开发经验,Patrick 了解开发的各个阶段,在传染病、肿瘤学和炎症,以及新颖的早期开发计划设计,乃至应用建模和模拟来解决关键开发问题方面都具有特定的专业知识。Patrick 曾在 NEJM 和 Lancet 等期刊上发表过 125 篇以上同行评审的文章。

SELECT PUBLICATIONS

Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Dosing will be a key success factor in repurposing antivirals for COVID-19. Br J Clin Pharmacol. 2020;10.1111/bcp.14314.

Rayner CR, Smith PF, Hershberger K, Wesche D. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Clin Transl Sci. 2020;10.1111/cts.12790.

Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., Smith, P., Perelson, A. S., & Guedj, J. (2020). Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT: pharmacometrics & systems pharmacology, 10.1002/psp4.12543. https://doi.org/10.1002/psp4.12543

Sloan, S. E., Szretter, K. J., Sundaresh, B., Narayan, K. M., Smith, P., Skurnik, D., Bedard, S., Trevejo, J. M., Oldach, D., & Shriver, Z. (2020). Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral research, 104763. Advance online publication. https://doi.org/10.1016/j.antiviral.2020.104763

Patel, K., Kirkpatrick, C. M., Nieforth, K. A., Chanda, S., Zhang, Q., McClure, M., Fry, J., Symons, J. A., Blatt, L. M., Beigelman, L., DeVincenzo, J. P., Huntjens, D. R., & Smith, P. F. (2019). Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. The Journal of antimicrobial chemotherapy, 74(2), 442–452. https://doi.org/10.1093/jac/dky415

Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol. 2017 Jul;83(7):1580-1594.

AM Wollacott, MF Boni, KJ Szretter, SE Sloan, M Yousofshahi, K Viswanathan, S Bedard, CA Hay, PF Smith, Z Shriver, JM Trevejo. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. EBioMedicine 5 (2016), 147-155.

JP DeVincenzo, MW McClure, JA Symons, H Fathi, C Westland, S Chanda, R Lambkin-Williams, P Smith, Q Zhang,L Beigelman,LM. Blatt, J Fry. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine 11/2015; 373(21):2048-2058.

Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010 Oct 30;376(9751):1467-75.

返回顶部
Powered by Translations.com GlobalLink OneLink Software